Literature DB >> 2476845

The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration.

P Garred1, T E Michaelsen, A Aase.   

Abstract

Using a matched series of human-mouse chimaeric IgG anti-5-iodo-4-hydroxy-3-nitrophenacetyl (anti-NIP) antibodies and NIP-bovine serum albumin (NIP-BSA) we examined how different variables influence the activation pattern of complement. When BSA was used with different hapten densities and the input of NIP-BSA was altered, we observed a change in the subclass reaction pattern. IgG3 fixed more Clq than IgG1 and IgG2 in all situations. IgG1 was slightly better than IgG3 and IgG2 at high antigen concentrations at activating C4 and C3 and inducing formation of the terminal complement complex (TCC). When the epitope density and/or the NIP-BSA concentration was reduced, IgG3 became best, followed by IgG1 and IgG2. IgG1 now revealed a marked prozone. Furthermore, IgG4 was found to activate C3 and mediate TCC formation at high epitope and complement concentrations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476845     DOI: 10.1111/j.1365-3083.1989.tb01225.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  26 in total

1.  IgG subclass distribution in serum and rectal mucosa of monozygotic twins with or without inflammatory bowel disease.

Authors:  L Helgeland; C Tysk; G Järnerot; K Kett; E Lindberg; D Danielsson; S N Andersen; P Brandtzaeg
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

2.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

3.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

4.  Serum IgG subclass antibodies to a variety of food antigens in patients with coeliac disease.

Authors:  M Hvatum; H Scott; P Brandtzaeg
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

5.  Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine.

Authors:  A Aase; G Bjune; E A Høiby; E Rosenqvist; A K Pedersen; T E Michaelsen
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 6.  Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.

Authors:  Alexander Faje
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

Review 7.  Antibody Isotypes for Tumor Immunotherapy.

Authors:  Anna Kretschmer; Ralf Schwanbeck; Thomas Valerius; Thies Rösner
Journal:  Transfus Med Hemother       Date:  2017-09-07       Impact factor: 3.747

8.  Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Authors:  N Ruijne; R A Lea; J O'Hallahan; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2006-07

9.  Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.

Authors:  S Giuntini; D M Granoff; P T Beernink; O Ihle; D Bratlie; T E Michaelsen
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

10.  Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.

Authors:  R G Bredius; P C Driedijk; M F Schouten; R S Weening; T A Out
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.